A citation-based method for searching scientific literature


List of co-cited articles
414 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Thomas Nyström, Mark K Gutniak, Qimin Zhang, Fan Zhang, Jens Juul Holst, Bo Ahrén, Ake Sjöholm. Am J Physiol Endocrinol Metab 2004
444
16


Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
David C Klonoff, John B Buse, Loretta L Nielsen, Xuesong Guan, Christopher L Bowlus, John H Holcombe, Matthew E Wintle, David G Maggs. Curr Med Res Opin 2008
489
14

Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
Hisko Oeseburg, Rudolf A de Boer, Hendrik Buikema, Pim van der Harst, Wiek H van Gilst, Herman H W Silljé. Arterioscler Thromb Vasc Biol 2010
164
14


GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Mohammad Hossein Noyan-Ashraf, M Abdul Momen, Kiwon Ban, Al-Muktafi Sadi, Yu-Qing Zhou, Ali M Riazi, Laurie L Baggio, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2009
366
12


Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress.
A Ceriello, F Mercuri, L Quagliaro, R Assaloni, E Motz, L Tonutti, C Taboga. Diabetologia 2001
277
12

Liraglutide as additional treatment for type 1 diabetes.
Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
89
12

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
844
10

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon. Circulation 2004
593
10


The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
10


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
10

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
10

Incretin-based therapies for type 2 diabetes mellitus.
Julie A Lovshin, Daniel J Drucker. Nat Rev Endocrinol 2009
449
10

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
959
10


Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Amal K Bose, Mihaela M Mocanu, Richard D Carr, Christian L Brand, Derek M Yellon. Diabetes 2005
412
10

The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes.
Antonio Ceriello, Katherine Esposito, Roberto Testa, Anna Rita Bonfigli, Maurizio Marra, Dario Giugliano. Diabetes Care 2011
89
10

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
Mary Ann Huang, Joel K Greenson, Cewin Chao, Lilian Anderson, Debra Peterman, Jon Jacobson, Dawn Emick, Anna S Lok, Hari S Conjeevaram. Am J Gastroenterol 2005
274
8

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
8

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Renata Belfort, Stephen A Harrison, Kenneth Brown, Celia Darland, Joan Finch, Jean Hardies, Bogdan Balas, Amalia Gastaldelli, Fermin Tio, Joseph Pulcini,[...]. N Engl J Med 2006
8

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.
Kittichai Promrat, David E Kleiner, Heather M Niemeier, Elizabeth Jackvony, Marie Kearns, Jack R Wands, Joseph L Fava, Rena R Wing. Hepatology 2010
639
8

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
S M Grundy, I J Benjamin, G L Burke, A Chait, R H Eckel, B V Howard, W Mitch, S C Smith, J R Sowers. Circulation 1999
8

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts.
Tingcun Zhao, Pratik Parikh, Siva Bhashyam, Hakki Bolukoglu, Indu Poornima, You-Tang Shen, Richard P Shannon. J Pharmacol Exp Ther 2006
214
8

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
8

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
Kristine B Degn, Birgitte Brock, Claus B Juhl, Christian B Djurhuus, Jaime Grubert, Dennis Kim, Jenny Han, Kristin Taylor, Mark Fineman, Ole Schmitz. Diabetes 2004
176
8




Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
681
8


Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.
John Dupré, Margaret T Behme, Thomas J McDonald. J Clin Endocrinol Metab 2004
88
8

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
474
8

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Richard E Pratley, Michael Nauck, Timothy Bailey, Eduard Montanya, Robert Cuddihy, Sebastiano Filetti, Anne Bloch Thomsen, Rie Elvang Søndergaard, Melanie Davies. Lancet 2010
395
8


Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
366
8

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
T Vilsbøll, J Rosenstock, H Yki-Järvinen, W T Cefalu, Y Chen, E Luo, B Musser, P J Andryuk, Y Ling, K D Kaufman,[...]. Diabetes Obes Metab 2010
225
8

The role of adjunctive exenatide therapy in pediatric type 1 diabetes.
Vandana S Raman, Kimberly J Mason, Luisa M Rodriguez, Krishnavathana Hassan, Xiaoying Yu, Lisa Bomgaars, Rubina A Heptulla. Diabetes Care 2010
52
8

Oxidative stress and diabetic complications.
Ferdinando Giacco, Michael Brownlee. Circ Res 2010
8




Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
Urd Kielgast, Jens J Holst, Sten Madsbad. Curr Diabetes Rev 2009
34
8

Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
M K Gutniak, L Juntti-Berggren, P M Hellström, A Guenifi, J J Holst, S Efendic. Diabetes Care 1996
59
6

Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat.
V Bucinskaite, T Tolessa, J Pedersen, B Rydqvist, L Zerihun, J J Holst, P M Hellström. Neurogastroenterol Motil 2009
81
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.